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K
umagai et al. de-
scribe how cy-
clin-dependent 
kinases (Cdks) initiate 
DNA replication by pro-
moting the interaction of 
two proteins conserved 
from yeast to mammals.
In budding yeast, 
Cdks phosphorylate two 
replication origin proteins 
called Sld2 and Sld3, allowing them to bind a third protein 
called Dpb11. Together, these proteins recruit Cdc45, which then 
promotes the activation of the MCM helicase complex to separate 
the two strands of DNA and initiate replication. Whether the 
same system operates in higher organisms is unclear because the 
vertebrate homologues of Sld2 and Sld3 have remained obscure.
<addart type=”rel” doi=”10.1083/jcb.201102003”>Kumagai et al. </addart> previously identifi  ed a protein called Treslin 
as a candidate homologue of Sld3. Treslin is required for DNA 
replication in Xenopus egg extracts and human cells, and it binds 
to TopBP1—the vertebrate homologue of Dpb11—in the presence 
of Cdks. The researchers now show that Cdks phosphorylate 
Treslin on a specifi  c serine residue in a region of the protein that 
associates with TopBP1 and that is relatively similar in sequence 
to yeast Sld3. When this serine was mutated to alanine, Treslin 
could no longer bind to TopBP1, and cells expressing this mutant 
instead of wild-type Treslin were unable to replicate their DNA. 
In addition, Treslin bound Xenopus Cdc45, suggesting that it 
really is the vertebrate orthologue of Sld3.
The authors now want to examine how Treslin and TopBP1 
integrate Cdc45 into the replication initiation complex. They also 
want to investigate why Cdks apparently phosphorylate additional 
sites in the Treslin sequence.
Kumagai, A., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201102003.
<doi>10.1083/jcb.1936iti2</doi><aid>jcb.1936iti2</aid><au>Ben Short</au><cor>bshort@rockefeller.edu</cor><ID>jcb.1936iti2fi g1.eps</ID><dochead>In This Issue</dochead><doctopic>News</doctopic>Epac1 cAMPs out at nuclear pores
T
he nucleoporin 
RanBP2 tethers a 
GTPase regulatory 
protein to nuclear pores, 
thereby limiting its ability 
to promote cell adhesion,  <addart type=”rel” doi=”10.1083/
jcb.201011126”>Gloerich et al. </addart> reveal.
Epac1 is a guanine 
nucleotide exchange fac-
tor that activates the Rap1 
GTPase to promote a variety of cellular functions, including intercel-
lular and cell–matrix adhesion. Epac1 itself is activated by several 
cell signaling pathways through the second messenger cAMP. In ad-
dition, the exchange factor is anchored by various proteins to specifi  c 
locations in the cell to control exactly where Rap1 is switched on.
Gloerich et al. discovered that Epac1 is anchored to the 
nuclear envelope by the nuclear pore protein RanBP2. However, 
the team found that Epac1 is kept inactive at this location because 
RanBP2’s zinc fingers bind directly to the exchange factor’s 
catalytic domain. Knocking down RanBP2 by RNAi released 
Epac1 into the cytoplasm and boosted its ability to activate Rap1 
and promote cell adhesion.
cAMP was unable to free Epac1 from RanBP2’s clutches, 
but the exchange factor was liberated at the onset of mitosis, when 
RanBP2’s zinc fi  ngers are phosphorylated by mitotic kinases. 
Senior author Johannes Bos doesn’t yet know the identity of these 
kinases, but he speculates that Epac1’s release in mitosis might 
help cells rapidly reestablish their contacts with neighboring 
cells and the extracellular matrix following cell division.
Gloerich, M., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201011126.
RanBP2 (red) anchors Epac1 (green) 
to the nuclear envelope in control cells 
(left), but RanBP2 knockdown leads to 
Epac1’s enrichment in the nucleus and 
cytoplasm (right).
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T
he Aurora A kinase may con-
tribute to polycystic kidney 
disease (PKD) by inactivat-
ing a key calcium channel in kidney 
cells,  <addart type=”rel” doi=”10.1083/jcb.201012061”>Plotnikova and Golemis </addart> say.
Aurora A is an oncogene best 
known as a regulator of mitotic pro-
gression. But the kinase has important 
functions during interphase as well, 
when it can promote cilia disassembly 
and can be activated by elevated cal-
cium levels. Because both calcium signaling and cilia are defective 
in PKD, Plotnikova and Golemis wondered whether Aurora might 
contribute to the pathology of this common genetic disease.
The researchers found that Aurora A was up-regulated and 
activated in epithelial cells lining the cysts in PKD patient kidneys. 
In addition, Aurora A bound to and phosphorylated a calcium 
channel called polycystin-2, whose gene, PKD2, is often mutated in 
autosomal dominant forms of PKD. This interaction was enhanced 
by Aurora A’s regulatory partner NEDD9.
Polycystin-2 mediates calcium infl   ux into cilia and the 
release of calcium from storage in the endoplasmic reticulum. 
Inhibition or knockdown of Aurora A boosted intracellular 
calcium levels, but this effect was less pronounced in kidney cells 
lacking polycystin-2, indicating that the kinase normally lowers 
calcium levels by inactivating this channel. Only small doses of 
inhibitor were required to increase calcium levels, suggesting 
that Aurora A may be a viable therapeutic target for boosting 
polycystin-2 activity in certain PKD patients. Senior author 
Erica Golemis now wants to investigate how Aurora A becomes 
up-regulated in PKD and whether inhibitors of the kinase can 
slow cystogenesis in mouse models of the disease.
Plotnikova, O.V., and E.A. Golemis. 2011. J. Cell Biol. doi:10.1083/
jcb.201012061.
DNA synthesis (indicated by green 
nuclei) occurs in cells expressing 
wild-type Treslin (left) but not in cells 
expressing a nonphosphorylatable 
version of the protein (right).
Red staining indicates the 
presence of activated Aurora 
A in the epithelial cells lining 
cysts in PKD patient kidneys.